Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma
Martina Mang Leng Lei(Hong Kong Polytechnic University), Terence K. Lee(Hong Kong Polytechnic University)
Cited by 3
Related Papers
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications
|Nature Reviews Gastroenterology & Hepatology|2021|472
EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma
|Cancer Research|2021|130
Caspase-3–Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma
|Cancer Research|2022|106